Influenza
Conditions
Keywords
Prevention
Brief summary
Flublok was studied previously in children 6 -59 months of age and demonstrated less than satisfactory immunogenicity results, especially in the 6-36 month age group. Thus, the initial introduction of Flublok Quadrivalent Formulation (RIV4) into the pediatric population will evaluate immunogenicity and safety older children and adolescents, aged 6-17. This clinical trial is designed to demonstrate safety and non-inferior immunogenicity of Flublok-Q in pediatric subjects 6-17 years of age as compared to IIV4. Positive results in this study may support further studies in younger children.
Detailed description
The U.S. Advisory Committee on Immunization Practices (ACIP) recommends that all people ≥6 months of age receive influenza vaccine annually. Recommendations for influenza immunization of children vary somewhat among countries in the European Union, but immunization of children at high risk for complications of influenza infection is recommended by WHO and according to criteria in most countries. Currently, the immunization practices are progressing to quadrivalent formulations of inactivated influenza vaccines (IIV4) which are approved in the US for most of the indicated population. Additionally, live attenuated vaccine (LAIV4) is approved in the U.S. for individuals aged 2-49 years and Flublok®(RIV3), a purified trivalent recombinant hemagglutinin protein vaccine is approved in the U.S. for adults 18-49 years of age. Children are at particular risk of complications of influenza, including the B lineages, so expansion of the Flublok indication into the pediatric age group with a quadrivalent formulation is warranted.
Interventions
BIOLOGICALFlublok® Quadrivalent Influenza Virus Vaccine
Intramuscular (Relevant year formulation)
BIOLOGICALFluarix Quadrivalent® Influenza Virus Vaccine
Intramuscular (Relevant year formulation)
Sponsors
Protein Sciences Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female age 6-17 years (Cohort A: 6-8 years of age; Cohort B: 9-17 years of age) 2. Female subjects of child-bearing potential (as defined by the onset of menses) must agree to avoid becoming pregnant and to use effective method of contraception or practice abstinence for at least 28 day prior to the first study vaccine administration, until the completion of the study. Female subjects of child-bearing potential must have a negative pregnancy test within 24 hours prior to vaccine administration. 3. In good general health, as determined by medical history and targeted physical examination, if indicated The parent(s) or legal representative(s) of each potential subject must: 1. Comprehend the study requirements and agree to comply with planned study procedures and visits 2. Provide written consent prior to enrollment and initiation of any study procedures Pediatric assent will be obtained in accordance with the Institutional Review Board/Independent Ethics Committee determination.
Exclusion criteria
1. Known allergy to eggs, severe allergy (e.g. anaphylaxis) to other components of either vaccine or contraindications to receipt of the comparator IIV4 2. Immunosuppression as a result of an underlying illness or treatment. Note: Subjects on nasal or topical steroids will be allowed 3. Active neoplastic disease or a history of any malignancy. 4. History of receiving influenza vaccine within the past 6 months or plans during the study to receive influenza vaccine outside of this study. 5. History of receiving immunoglobulin or other blood product within the 3 months prior to enrollment in this study. 6. Receipt of any non-study licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study, or plans during the study to receive a licensed vaccine within 4 weeks of a study dose \[See above for influenza vaccines\]. 7. Acute or chronic medical condition that, in the opinion of the investigator, would render immunization unsafe or would interfere with the evaluation of immune responses 8. History of severe reactions following immunization. 9. An acute illness, including a body temperature greater than 100\*F, within 3 days prior to immunization. 10. Receipt of an experimental vaccine or medication within 1 month prior to enrollment in this study, or expectation of receiving an experimental vaccine, medication, or blood product during the study Stage in which the subject will participate. 11. Developmental delay, neurologic disorder, or seizure disorder requiring ongoing medical management (note: history of seizure is not an exclusion criterion). 12. Any other condition or situation that would, in the opinion of the investigator, place the potential subject an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol. 13. History of Guillain-Barré syndrome. 14. Known pregnancy, positive urine or serum pregnancy test within 24 hours prior to planned study vaccination, or breast-feeding. 15. Concurrent participation in another clinical trial (in active or follow-up phase).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Day 0 up to Day 28 post vaccination | Solicited injection site reactions: Pain, Bruising, Redness, and Swelling; Solicited systemic reactions: Headache, Chills, Fever, Fatigue, Muscle Pain, Joint Pain and Nausea. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 and Day 28 after final vaccination (Cohort B includes 1-Dose subjects at Day 28 and 2-Dose subjects at Day 56) | Immunogenicity will be evaluated prior to vaccination and at 28 days after vaccination using the hemagglutination inhibition (HAI) technique. For each influenza vaccine strain, pre and post vaccination geometric mean titers (GMTs) and seroprotection and seroconversion will be calculated. |
| Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 after final vaccination | Seroconversion is defined as: Either a pre vaccination titer \< 10 (1/dil) and a post vaccination titer ≥ 40 (1/dil), or a pre vaccination titer ≥ 10 (1/dil) and a ≥ 4 fold increase in post vaccination titer at Day 28 after the final vaccination. |
| Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 after final vaccination | Seroprotection is defined as: A titer ≥ 40 (l/dil) at pre vaccination and at Day 28 after the final vaccination. |
Countries
United States
Participant flow
Pre-assignment details
The randomized population (219 subjects) includes all subjects who were randomized and the safety population (217 subjects) includes all randomized subjects who received any dose of study vaccine and provided any safety. Two (2) randomized subjects did not fit the criteria to be included in the safety population and were excluded from the analysis.
Participants by arm
| Arm | Count |
|---|---|
| Study Group 1, Flublok Cohort A Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation) | 80 |
| Study Group 2, Fluarix Cohort A Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation) | 78 |
| Study Group 3, Flublok Cohort B Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation) | 28 |
| Study Group 4, Fluarix Cohort B Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation) | 31 |
| Total | 217 |
Baseline characteristics
| Characteristic | Total | Study Group 1, Flublok Cohort A | Study Group 2, Fluarix Cohort A | Study Group 3, Flublok Cohort B | Study Group 4, Fluarix Cohort B |
|---|---|---|---|---|---|
| Age, Customized 6-8 years | 59 participants | 0 participants | 0 participants | 28 participants | 31 participants |
| Age, Customized 9-17 years | 158 participants | 80 participants | 78 participants | 0 participants | 0 participants |
| Region of Enrollment United States | 217 participants | 80 participants | 78 participants | 28 participants | 31 participants |
| Sex: Female, Male Female | 111 Participants | 42 Participants | 40 Participants | 17 Participants | 12 Participants |
| Sex: Female, Male Male | 106 Participants | 38 Participants | 38 Participants | 11 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 9 / 80 | 10 / 28 | 14 / 78 | 17 / 31 |
| serious Total, serious adverse events | 0 / 80 | 0 / 28 | 0 / 78 | 1 / 31 |
Outcome results
Primary
Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine.
Solicited injection site reactions: Pain, Bruising, Redness, and Swelling; Solicited systemic reactions: Headache, Chills, Fever, Fatigue, Muscle Pain, Joint Pain and Nausea.
Time frame: Day 0 up to Day 28 post vaccination
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Study Group 1, Flublok Cohort A | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Solicited Systemic Events | 47 participants |
| Study Group 1, Flublok Cohort A | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Unsolicited Adverse Events | 19 participants |
| Study Group 1, Flublok Cohort A | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Solicited Local Events | 39 participants |
| Study Group 3, Flublok Cohort B | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Solicited Systemic Events | 16 participants |
| Study Group 3, Flublok Cohort B | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Unsolicited Adverse Events | 13 participants |
| Study Group 3, Flublok Cohort B | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Solicited Local Events | 14 participants |
| Study Group 2, Fluarix Cohort A | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Solicited Local Events | 42 participants |
| Study Group 2, Fluarix Cohort A | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Solicited Systemic Events | 53 participants |
| Study Group 2, Fluarix Cohort A | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Unsolicited Adverse Events | 26 participants |
| Study Group 4, Fluarix Cohort B | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Solicited Systemic Events | 18 participants |
| Study Group 4, Fluarix Cohort B | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Unsolicited Adverse Events | 15 participants |
| Study Group 4, Fluarix Cohort B | Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine. | Solicited Local Events | 14 participants |
Secondary
Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine
Immunogenicity will be evaluated prior to vaccination and at 28 days after vaccination using the hemagglutination inhibition (HAI) technique. For each influenza vaccine strain, pre and post vaccination geometric mean titers (GMTs) and seroprotection and seroconversion will be calculated.
Time frame: Day 0 and Day 28 after final vaccination (Cohort B includes 1-Dose subjects at Day 28 and 2-Dose subjects at Day 56)
Population: The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and \~28 days following completion of immunization (\~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Study Group 1, Flublok Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - A/Texas/50/2012 | 852.30 titer |
| Study Group 1, Flublok Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - A/California/7/2009 | 54.94 titer |
| Study Group 1, Flublok Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - A/California/7/2009 | 914.92 titer |
| Study Group 1, Flublok Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - A/Texas/50/2012 | 181.57 titer |
| Study Group 1, Flublok Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - B/Massachusetts/2/2012 | 20.44 titer |
| Study Group 1, Flublok Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - B/Massachusetts/2/2012 | 161.02 titer |
| Study Group 1, Flublok Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - B/Brisbane/60/2008 | 12.49 titer |
| Study Group 1, Flublok Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - B/Brisbane/60/2008 | 51.73 titer |
| Study Group 3, Flublok Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - A/California/7/2009 | 564.23 titer |
| Study Group 3, Flublok Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - A/Texas/50/2012 | 141.91 titer |
| Study Group 3, Flublok Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - B/Massachusetts/2/2012 | 21.17 titer |
| Study Group 3, Flublok Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - B/Brisbane/60/2008 | 59.67 titer |
| Study Group 3, Flublok Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - B/Massachusetts/2/2012 | 119.96 titer |
| Study Group 3, Flublok Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - A/Texas/50/2012 | 531.36 titer |
| Study Group 3, Flublok Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - B/Brisbane/60/2008 | 10.56 titer |
| Study Group 3, Flublok Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - A/California/7/2009 | 59.79 titer |
| Study Group 2, Fluarix Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - B/Brisbane/60/2008 | 73.82 titer |
| Study Group 2, Fluarix Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - B/Brisbane/60/2008 | 11.43 titer |
| Study Group 2, Fluarix Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - A/California/7/2009 | 1224.31 titer |
| Study Group 2, Fluarix Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - A/California/7/2009 | 85.89 titer |
| Study Group 2, Fluarix Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - A/Texas/50/2012 | 272.74 titer |
| Study Group 2, Fluarix Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - B/Massachusetts/2/2012 | 111.14 titer |
| Study Group 2, Fluarix Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - A/Texas/50/2012 | 1071.58 titer |
| Study Group 2, Fluarix Cohort A | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - B/Massachusetts/2/2012 | 13.89 titer |
| Study Group 4, Fluarix Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - A/Texas/50/2012 | 629.48 titer |
| Study Group 4, Fluarix Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - B/Massachusetts/2/2012 | 12.19 titer |
| Study Group 4, Fluarix Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - B/Massachusetts/2/2012 | 122.90 titer |
| Study Group 4, Fluarix Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - A/California/7/2009 | 695.03 titer |
| Study Group 4, Fluarix Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - B/Brisbane/60/2008 | 9.36 titer |
| Study Group 4, Fluarix Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - A/California/7/2009 | 57.04 titer |
| Study Group 4, Fluarix Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 0 - A/Texas/50/2012 | 161.32 titer |
| Study Group 4, Fluarix Cohort B | Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | Day 28 - B/Brisbane/60/2008 | 60.74 titer |
Secondary
Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine
Seroconversion is defined as: Either a pre vaccination titer \< 10 (1/dil) and a post vaccination titer ≥ 40 (1/dil), or a pre vaccination titer ≥ 10 (1/dil) and a ≥ 4 fold increase in post vaccination titer at Day 28 after the final vaccination.
Time frame: Day 28 after final vaccination
Population: The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and \~28 days following completion of immunization (\~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Study Group 1, Flublok Cohort A | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H1N1: A/California/07/2009 | 87 percentage of participants |
| Study Group 1, Flublok Cohort A | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H3N2: A/Texas/50/2012 | 59 percentage of participants |
| Study Group 1, Flublok Cohort A | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Massachusetts/2/2012 | 69 percentage of participants |
| Study Group 1, Flublok Cohort A | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Brisbane/60/2008 | 52 percentage of participants |
| Study Group 3, Flublok Cohort B | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H3N2: A/Texas/50/2012 | 49 percentage of participants |
| Study Group 3, Flublok Cohort B | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Massachusetts/2/2012 | 61 percentage of participants |
| Study Group 3, Flublok Cohort B | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Brisbane/60/2008 | 67 percentage of participants |
| Study Group 3, Flublok Cohort B | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H1N1: A/California/07/2009 | 68 percentage of participants |
| Study Group 2, Fluarix Cohort A | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Massachusetts/2/2012 | 77 percentage of participants |
| Study Group 2, Fluarix Cohort A | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H3N2: A/Texas/50/2012 | 54 percentage of participants |
| Study Group 2, Fluarix Cohort A | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Brisbane/60/2008 | 69 percentage of participants |
| Study Group 2, Fluarix Cohort A | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H1N1: A/California/07/2009 | 88 percentage of participants |
| Study Group 4, Fluarix Cohort B | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Brisbane/60/2008 | 73 percentage of participants |
| Study Group 4, Fluarix Cohort B | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H3N2: A/Texas/50/2012 | 50 percentage of participants |
| Study Group 4, Fluarix Cohort B | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H1N1: A/California/07/2009 | 75 percentage of participants |
| Study Group 4, Fluarix Cohort B | Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Massachusetts/2/2012 | 82 percentage of participants |
Secondary
Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine
Seroprotection is defined as: A titer ≥ 40 (l/dil) at pre vaccination and at Day 28 after the final vaccination.
Time frame: Day 28 after final vaccination
Population: The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and \~28 days following completion of immunization (\~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Study Group 1, Flublok Cohort A | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H1N1: A/California/07/2009 | 97 percentage of participants |
| Study Group 1, Flublok Cohort A | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H3N2: A/Texas/50/2012 | 100 percentage of participants |
| Study Group 1, Flublok Cohort A | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Massachusetts/2/2012 | 91 percentage of participants |
| Study Group 1, Flublok Cohort A | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Brisbane/60/2008 | 78 percentage of participants |
| Study Group 3, Flublok Cohort B | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H3N2: A/Texas/50/2012 | 100 percentage of participants |
| Study Group 3, Flublok Cohort B | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Massachusetts/2/2012 | 90 percentage of participants |
| Study Group 3, Flublok Cohort B | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Brisbane/60/2008 | 86 percentage of participants |
| Study Group 3, Flublok Cohort B | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H1N1: A/California/07/2009 | 99 percentage of participants |
| Study Group 2, Fluarix Cohort A | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Massachusetts/2/2012 | 85 percentage of participants |
| Study Group 2, Fluarix Cohort A | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H3N2: A/Texas/50/2012 | 100 percentage of participants |
| Study Group 2, Fluarix Cohort A | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Brisbane/60/2008 | 85 percentage of participants |
| Study Group 2, Fluarix Cohort A | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H1N1: A/California/07/2009 | 100 percentage of participants |
| Study Group 4, Fluarix Cohort B | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Brisbane/60/2008 | 81 percentage of participants |
| Study Group 4, Fluarix Cohort B | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H3N2: A/Texas/50/2012 | 100 percentage of participants |
| Study Group 4, Fluarix Cohort B | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | H1N1: A/California/07/2009 | 100 percentage of participants |
| Study Group 4, Fluarix Cohort B | Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine | B/Massachusetts/2/2012 | 89 percentage of participants |